Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

BHRT RSS Feed
Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator InvestorStemCell, Gaintrader, HybridTrader
Search This Board:
Last Post: 11/22/2014 5:02:08 PM - Followers: 154 - Board type: Free - Posts Today: 11

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

MyoCell 

MyoCell SDF-1 


MyoCath


AdipoCell

Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  

 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

**Important: Mike Tomás' personal StemCellCEO blog!**
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
    
BHRT - Daily Candlesticks

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BHRT
Current Price
Volume:
Bid Ask Day's Range
Wiki
BHRT News: Securities Registration Statement (s-1) 11/21/2014 05:20:30 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 11/18/2014 09:57:48 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 11/18/2014 09:50:07 AM
BHRT News: Quarterly Report (10-q) 11/07/2014 06:02:26 AM
BHRT News: Small Company Offering and Sale of Securities Without Registration (d) 10/31/2014 04:35:33 PM
PostSubject
#11540  Sticky Note Bioheart, Inc. Completes Financing With Magna! HybridTrader 10/27/14 09:42:35 AM
#11517  Sticky Note Investing in Bioheart, Inc. $$$$$MUSTREAD$$$$ InvestorStemCell 10/26/14 05:19:10 PM
#6744  Sticky Note Bioheart Announces Positive 6 Month Data From Angel Gaintrader 04/03/14 05:59:37 PM
#12042   No, I had not seen that... diannedawn 11/22/14 05:02:08 PM
#12041   So sell your shares if you like. Never Gsdubb 11/22/14 02:59:36 PM
#12040   "It says it includes 87 million shares for Hopalongstocks 11/22/14 02:58:05 PM
#12039   It says it includes 87 million shares for Gsdubb 11/22/14 01:01:52 PM
#12038   " Like I said 143 million is not Hopalongstocks 11/22/14 12:58:13 PM
#12037   When I first bought shares there were 236,000,000 Gsdubb 11/22/14 12:37:24 PM
#12036   "The dilution is not as bad as I Hopalongstocks 11/22/14 12:27:45 PM
#12035   What are your thoughts on the S-1 filing? Gsdubb 11/22/14 11:08:57 AM
#12034   I know you look forward to posts from Gsdubb 11/22/14 11:08:21 AM
#12033   The dilution is not as bad as I Gsdubb 11/22/14 11:01:30 AM
#12032   I think you've summed it up nicely... diannedawn 11/22/14 09:20:10 AM
#12030   Look at just the $205K note, what the Hopalongstocks 11/21/14 09:32:09 PM
#12029   I'll tell you exactly what it says. It andyshow 11/21/14 07:45:36 PM
#12028   Magna MEGA DILUTION about to begin it looks Hopalongstocks 11/21/14 07:34:28 PM
#12027   http://ih.advfn.com/p.php?pid=nmona&article=64527836&xref=newsalert andyshow 11/21/14 05:47:09 PM
#12024   "This is some good valuable analysis Hopalongstocks " Hopalongstocks 11/21/14 02:45:06 PM
#12023   "Here is my public 10K record of shares. Hopalongstocks 11/21/14 02:37:27 PM
#12022   This is some good valuable analysis Hopalongstocks Thanks. HowardLeonhardt 11/21/14 01:36:12 PM
#12021   Opens down 5% essentially, 3 seconds after market Hopalongstocks 11/21/14 10:48:07 AM
#12020   7% discount* typo. Also they have an impressive Gsdubb 11/21/14 07:31:18 AM
#12019   Well it looks like from my count of Gsdubb 11/21/14 12:08:11 AM
#12018   "That would be some pretty bad business plan Hopalongstocks 11/20/14 11:33:37 PM
#12017   im not interested enough to go through the BigAlBalbosci 11/20/14 10:56:36 PM
#12016   That would be some pretty bad business plan Gsdubb 11/20/14 10:49:51 PM
#12015   The ole "scientific advisory" board list is perhaps Hopalongstocks 11/20/14 10:31:51 PM
#12014   regardless of the outcome of BHRT, that list BigAlBalbosci 11/20/14 09:17:23 PM
#12013   Every single one of those companies is destroyed now? Gsdubb 11/20/14 09:14:43 PM
#12012   BigAl, Hopalongstocks 11/20/14 09:11:03 PM
#12011   Just posting publicly available facts like you is all Gsdubb 11/20/14 09:10:36 PM
#12010   A lot of very OLD info about Leonhardt Hopalongstocks 11/20/14 09:08:41 PM
#12009   Smallcapvoice?? BHRT paid $5,000 to smallcapvoice for Hopalongstocks 11/20/14 08:43:46 PM
#12008   In total Leonhardt Ventures and Howard Leonhardt have Gsdubb 11/20/14 07:43:39 PM
#12007   http://www.smallcapvoice.com/bhrt/info.html Gsdubb 11/20/14 07:08:15 PM
#12006   http://smallcapvoice.com/blog/5-28-14-smallcapvoice-interview-with-bioheart-inc- Gsdubb 11/20/14 07:07:33 PM
#12005   http://www.bioheartinc.com/assets/press/BIOHEARTANNOUNCESCLINICALTRIALSININDIA.p andyshow 11/20/14 07:04:12 PM
#12004   http://www.prnewswire.com/news-releases/leading-experts-endorse-biohearts-muscle Gsdubb 11/20/14 07:03:56 PM
#12003   Cereplast is a totally different industry and doesn't Gsdubb 11/20/14 07:03:48 PM
#12002   http://www.bioheartinc.com/assets/press/2BIOHEARTANNOUNCESGRANDOPENINGOFMAGNUMCE andyshow 11/20/14 07:03:31 PM
#12001   http://www.bioheartinc.com/assets/press/BIOHEARTRELEASESQ2FINANCIALINFORMATIONSH andyshow 11/20/14 07:03:05 PM
#12000   http://www.bioheartinc.com/assets/press/BioheartAnnouncesPartnershipinColombia.p andyshow 11/20/14 07:02:31 PM
#11999   http://www.bioheartinc.com/AboutUs/BoardOfDirectors Gsdubb 11/20/14 07:00:48 PM
#11998   http://www.bioheartinc.com/AboutUs/ScientificAdvisoryBoard Gsdubb 11/20/14 07:00:09 PM
#11997   www.BioHeartinc.com Gsdubb 11/20/14 06:53:06 PM
#11996   Here's some Magna "destruction" I found via a Hopalongstocks 11/20/14 06:06:22 PM
#11993   that part sounds ok BigAlBalbosci 11/20/14 06:01:19 PM
#11992   yea...On October 7, 2014, the Company entered into BigAlBalbosci 11/20/14 06:00:33 PM
#11991   YES:FL$T BigAlBalbosci 11/20/14 05:58:19 PM
#11990   "Equity purchase for $3 million at a%7" Hopalongstocks 11/20/14 05:57:38 PM
#11989   wow: During the nine months ended September 30, BigAlBalbosci 11/20/14 05:56:02 PM
#11988   "Purchase at a 7% discount. Hopalongstocks 11/20/14 05:52:24 PM
PostSubject